A highly-sensitive cell free DNA assay in gastrointestinal tumors - A prospective observational study
Not Applicable
Not yet recruiting
- Conditions
- Gastrointestinal malignant tumors
- Registration Number
- JPRN-UMIN000050428
- Lead Sponsor
- Aichi Cancer Network
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
1) The patient has active overlapping cancers (concurrent overlapping/multiple cancers). 2) Other conditions deemed inappropriate by the physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cfDNA dynamics (Percentage of cfDNA detected at each test time point and its trend)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cfDNA detection in gastrointestinal tumors as studied in JPRN-UMIN000050428?
How does the highly-sensitive cfDNA assay in JPRN-UMIN000050428 compare to standard-of-care diagnostics for gastrointestinal cancers?
What biomarkers are being evaluated in JPRN-UMIN000050428 to predict treatment response in gastrointestinal tumor patients?
What adverse events are associated with cfDNA-based monitoring in gastrointestinal malignancies and how are they managed?
What are the potential applications of cfDNA assays in combination with other therapies for gastrointestinal tumor management?